Acumen Pharmaceuticals (ABOS) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Passage Bio (PASG) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 49.3% versus a loss of 88.1%. Over five years, PASG leads with a -97.3% price change compared with -97.7% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $12.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | PASG |
|---|---|---|
| Share price | $0.1865 | $3.92 |
| Market cap | $13.49M | $12.61M |
| 1-day change | -3.52% | +11.68% |
| YTD return | -91.16% | -66.78% |
| 1-year return | -88.12% | -49.32% |
| 5-year return | -97.74% | -97.30% |
| EPS (TTM) | $-1.55 | $-10.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-121.33M | $-45.52M |
| 52-week high | $3.60 | $20.00 |
| 52-week low | $0.16 | $3.29 |
| Distance from 52-week high | -94.82% | -80.40% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +3975.07% | +295.41% |
| Average volume | 2.73M | 20.77K |
| Shares outstanding | 72.33M | 3.22M |
| Employees | 60 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed ABOS by 38.8 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
ABOS vs PASG FAQ
Which is bigger, Acumen Pharmaceuticals or Passage Bio?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $12.61M for Passage Bio (PASG).
Which stock has performed better over the past year, ABOS or PASG?
PASG returned -49.32% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.